Internal bleeding detection device developer Saranas said today it raised $2.8 million in a Series C funding round slated to support its Early Bird bleeding monitor system.
The Early bird device is designed as a standard vascular access sheath which is embedded with sensors which detect bleeding from accidentally ruptured blood vessels during cardiac procedures, including transcatheter aortic valve replacements, the Houston, Texas-based company said.
Funds from the round will be used to support a multicenter clinical pilot trial of the Early Bird system in the US, as well as the company’s continued commercialization plan.
“We are pleased to bring additional investment and appreciate the confidence shown by so many returning investors. We continue our work to deliver a product to market that has the potential to significantly reduce bleeding complications while reducing related costs to providers and the healthcare system. Since our last round of financing, we have completed design verification and validation activities, continued to build our growing intellectual property portfolio, and submitted a De Novo application to the FDA. With this investment, we are well positioned to initiate a multicenter clinical pilot and extend access to this innovative device to patients in the U.S.,” prez & CEO Zaffer Syed said in a press release.
Saranas did not announce any participants in the round.
Late last month, Saranas said that it submitted an FDA application seeking de novo classification for its Early Bird bleed monitoring system.
